JPWO2021178933A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021178933A5 JPWO2021178933A5 JP2022553203A JP2022553203A JPWO2021178933A5 JP WO2021178933 A5 JPWO2021178933 A5 JP WO2021178933A5 JP 2022553203 A JP2022553203 A JP 2022553203A JP 2022553203 A JP2022553203 A JP 2022553203A JP WO2021178933 A5 JPWO2021178933 A5 JP WO2021178933A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- endonuclease
- nuclease system
- seq
- engineered nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004533 Endonucleases Human genes 0.000 claims 32
- 108010042407 Endonucleases Proteins 0.000 claims 32
- 101710163270 Nuclease Proteins 0.000 claims 30
- 239000002773 nucleotide Substances 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 108020004414 DNA Proteins 0.000 claims 14
- 102000053602 DNA Human genes 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 229920002477 rna polymer Polymers 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 4
- 238000010845 search algorithm Methods 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 239000004407 iron oxides and hydroxides Substances 0.000 claims 1
- 230000030648 nucleus localization Effects 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024216978A JP2025060673A (ja) | 2020-03-06 | 2024-12-11 | クラスｉｉのｖ型ｃｒｉｓｐｒ系 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986477P | 2020-03-06 | 2020-03-06 | |
| US62/986,477 | 2020-03-06 | ||
| US202063022276P | 2020-05-08 | 2020-05-08 | |
| US63/022,276 | 2020-05-08 | ||
| US202063045815P | 2020-06-29 | 2020-06-29 | |
| US63/045,815 | 2020-06-29 | ||
| US202063068316P | 2020-08-20 | 2020-08-20 | |
| US63/068,316 | 2020-08-20 | ||
| US202063069699P | 2020-08-24 | 2020-08-24 | |
| US63/069,699 | 2020-08-24 | ||
| US202063116157P | 2020-11-19 | 2020-11-19 | |
| US63/116,157 | 2020-11-19 | ||
| PCT/US2021/021259 WO2021178933A2 (en) | 2020-03-06 | 2021-03-06 | Class ii, type v crispr systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024216978A Division JP2025060673A (ja) | 2020-03-06 | 2024-12-11 | クラスｉｉのｖ型ｃｒｉｓｐｒ系 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023517041A JP2023517041A (ja) | 2023-04-21 |
| JPWO2021178933A5 true JPWO2021178933A5 (https=) | 2024-07-24 |
| JP2023517041A5 JP2023517041A5 (https=) | 2024-07-24 |
| JP7605852B2 JP7605852B2 (ja) | 2024-12-24 |
Family
ID=77612848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553203A Active JP7605852B2 (ja) | 2020-03-06 | 2021-03-06 | クラスｉｉのｖ型ｃｒｉｓｐｒ系 |
| JP2024216978A Pending JP2025060673A (ja) | 2020-03-06 | 2024-12-11 | クラスｉｉのｖ型ｃｒｉｓｐｒ系 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024216978A Pending JP2025060673A (ja) | 2020-03-06 | 2024-12-11 | クラスｉｉのｖ型ｃｒｉｓｐｒ系 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11713471B2 (https=) |
| EP (1) | EP4114932A4 (https=) |
| JP (2) | JP7605852B2 (https=) |
| KR (2) | KR102647766B1 (https=) |
| CN (1) | CN116096876A (https=) |
| AU (2) | AU2021231074C1 (https=) |
| CA (1) | CA3174557A1 (https=) |
| GB (2) | GB2617658B (https=) |
| MX (1) | MX2022011039A (https=) |
| WO (1) | WO2021178933A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3830301B1 (en) | 2018-08-01 | 2024-05-22 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
| GB2617658B (en) | 2020-03-06 | 2024-04-17 | Metagenomi Inc | Class II, type V CRISPR systems |
| JP2023548588A (ja) * | 2020-10-30 | 2023-11-17 | アーバー バイオテクノロジーズ， インコーポレイテッド | Ｔｒａｃを標的とするｒｎａガイドを含む組成物及びその使用 |
| US20230072431A1 (en) * | 2020-11-03 | 2023-03-09 | Science Solutions Llc | Novel class 2 crispr-cas rna-guided endonucleases |
| US20240376451A1 (en) * | 2021-01-07 | 2024-11-14 | Inscripta, Inc. | Mad nucleases |
| KR20240017367A (ko) * | 2021-06-02 | 2024-02-07 | 메타지노미, 인크. | 클래스 ii, v형 crispr 시스템 |
| WO2023056291A1 (en) | 2021-09-28 | 2023-04-06 | Acrigen Biosciences | Compositions and methods for nucleic acid modifications |
| CN117050973B (zh) * | 2021-10-29 | 2024-07-19 | 山东舜丰生物科技有限公司 | 新型Cas酶和系统以及应用 |
| WO2023092132A1 (en) * | 2021-11-22 | 2023-05-25 | Mammoth Biosciences, Inc. | Effector proteins and uses thereof |
| CN116200368A (zh) * | 2021-11-30 | 2023-06-02 | 上海科技大学 | 一种基于c2c9核酸酶的新型基因组编辑系统及其应用 |
| AU2023209457A1 (en) * | 2022-01-21 | 2024-08-08 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| US12264328B2 (en) | 2022-07-18 | 2025-04-01 | ReNAgade Therapeutics Management, Inc. | Gene editing components, systems, and methods of use |
| JP2025525569A (ja) * | 2022-07-18 | 2025-08-05 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 遺伝子編集成分、システム、及び使用方法 |
| WO2024042168A1 (en) * | 2022-08-26 | 2024-02-29 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases |
| WO2024107665A1 (en) * | 2022-11-14 | 2024-05-23 | Mammoth Biosciences, Inc. | Effector proteins, compositions, systems and methods of use thereof |
| TW202440913A (zh) * | 2022-12-08 | 2024-10-16 | 香港商正基基因科技有限公司 | Cas12蛋白、CRISPR-Cas系統及其用途 |
| JP2026501682A (ja) * | 2023-01-03 | 2026-01-16 | エメンドバイオ・インコーポレイテッド | Ｏｍｎｉ ｘｌ１～２２ ｃｒｉｓｐｒヌクレアーゼ |
| WO2025003358A2 (en) * | 2023-06-29 | 2025-01-02 | UCB Biopharma SRL | Novel nucleic acid targeting systems comprising rna-guided nucleases |
| WO2025051140A1 (zh) * | 2023-09-04 | 2025-03-13 | 中国农业大学 | 新型CRISPR-Casσ酶和系统 |
| CN118773168B (zh) * | 2023-11-24 | 2025-07-25 | 华智生物技术有限公司 | CRISPR/Cas效应蛋白HT001及系统与应用 |
| EP4574975A1 (en) * | 2023-12-20 | 2025-06-25 | Bayer AG | Compositions and methods for delivering transgenes |
| WO2025201316A1 (zh) * | 2024-03-25 | 2025-10-02 | 深圳华大生命科学研究院 | 一种CRISPR-Cas系统 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9963689B2 (en) | 2013-12-31 | 2018-05-08 | The Regents Of The University Of California | Cas9 crystals and methods of use thereof |
| EP3889260A1 (en) | 2014-12-12 | 2021-10-06 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2017127807A1 (en) * | 2016-01-22 | 2017-07-27 | The Broad Institute Inc. | Crystal structure of crispr cpf1 |
| US20200263190A1 (en) * | 2016-04-19 | 2020-08-20 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| US20190161743A1 (en) | 2016-05-09 | 2019-05-30 | President And Fellows Of Harvard College | Self-Targeting Guide RNAs in CRISPR System |
| KR102758434B1 (ko) * | 2017-03-30 | 2025-01-21 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 게놈 편집에 의한 엑손 스키핑 유도 방법 |
| WO2018195545A2 (en) * | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| CA3102054A1 (en) * | 2017-06-05 | 2018-12-13 | Fred Hutchinson Cancer Research Center | Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies |
| US9982279B1 (en) * | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| JP2020536502A (ja) | 2017-09-07 | 2020-12-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 遺伝子操作のためのヌクレアーゼシステム |
| US20190247517A1 (en) | 2017-10-17 | 2019-08-15 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing for hemophilia a |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| JP7575271B2 (ja) | 2018-03-29 | 2024-10-29 | フェイト セラピューティクス，インコーポレイテッド | 操作された免疫エフェクター細胞およびその使用 |
| CA3109083A1 (en) | 2018-08-09 | 2020-02-13 | G+Flas Life Sciences | Compositions and methods for genome engineering with cas12a proteins |
| US12365888B2 (en) | 2018-12-14 | 2025-07-22 | Pioneer Hi-Bred International, Inc. | CRISPR-Cas systems for genome editing |
| EP3931313A2 (en) * | 2019-01-04 | 2022-01-05 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| AU2020223370B2 (en) | 2019-02-14 | 2023-04-20 | Metagenomi Therapeutics, Inc. | Enzymes with RuvC domains |
| CN110684823A (zh) | 2019-10-23 | 2020-01-14 | 海南大学 | 一种基于试纸条的Cas12a酶的微生物快速诊断技术 |
| CN110904239B (zh) | 2019-12-25 | 2020-11-10 | 武汉博杰生物医学科技有限公司 | 肺癌相关分子标志物基因突变的检测试剂盒与检测方法 |
| WO2021178934A1 (en) | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| GB2617658B (en) * | 2020-03-06 | 2024-04-17 | Metagenomi Inc | Class II, type V CRISPR systems |
| KR20230021657A (ko) | 2020-05-08 | 2023-02-14 | 메타지노미, 인크. | Ruvc 도메인을 포함하는 효소 |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| WO2022159742A1 (en) | 2021-01-22 | 2022-07-28 | Metagenomi, Inc | Novel engineered and chimeric nucleases |
| BR112023014719A2 (pt) | 2021-01-22 | 2023-12-05 | Metagenomi Inc | Novas nucleases quiméricas e manipuladas |
| EP4281567A4 (en) | 2021-01-25 | 2025-03-05 | The Broad Institute Inc. | REPROGRAMMABLE TNPB POLYPEPTIDES AND THEIR USE |
| BR112023018948A2 (pt) | 2021-03-19 | 2023-10-17 | Metagenomi Inc | Edição multiplex com enzimas cas |
| KR20240017367A (ko) | 2021-06-02 | 2024-02-07 | 메타지노미, 인크. | 클래스 ii, v형 crispr 시스템 |
| MX2024003007A (es) | 2021-09-08 | 2024-03-25 | Metagenomi Inc | Sistemas crispr de clase ii, tipo v. |
| EP4399290A4 (en) | 2021-09-08 | 2025-10-01 | Metagenomi Inc | CLASS II TYPE V CRISPR SYSTEMS |
-
2021
- 2021-03-06 GB GB2219438.5A patent/GB2617658B/en active Active
- 2021-03-06 KR KR1020227033789A patent/KR102647766B1/ko active Active
- 2021-03-06 AU AU2021231074A patent/AU2021231074C1/en active Active
- 2021-03-06 GB GB2205584.2A patent/GB2603704B/en active Active
- 2021-03-06 KR KR1020247008129A patent/KR20240036729A/ko active Pending
- 2021-03-06 MX MX2022011039A patent/MX2022011039A/es unknown
- 2021-03-06 JP JP2022553203A patent/JP7605852B2/ja active Active
- 2021-03-06 CN CN202180033688.1A patent/CN116096876A/zh active Pending
- 2021-03-06 WO PCT/US2021/021259 patent/WO2021178933A2/en not_active Ceased
- 2021-03-06 CA CA3174557A patent/CA3174557A1/en active Pending
- 2021-03-06 EP EP21763629.9A patent/EP4114932A4/en active Pending
-
2022
- 2022-03-28 US US17/706,466 patent/US11713471B2/en active Active
- 2022-09-06 US US17/929,978 patent/US20230227857A1/en active Pending
-
2023
- 2023-04-18 US US18/302,387 patent/US12123014B2/en active Active
-
2024
- 2024-02-01 AU AU2024200614A patent/AU2024200614A1/en active Pending
- 2024-12-11 JP JP2024216978A patent/JP2025060673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021178933A5 (https=) | ||
| JP6153180B2 (ja) | 脱塩基反応により標的化したｄｎａ配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体 | |
| CA3128755C (en) | Compositions and methods for treating hemoglobinopathies | |
| US20240344045A1 (en) | Enzymes with ruvc domains | |
| GB2605340A (en) | Base editing enzymes | |
| FI4118198T3 (fi) | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja käyttömenetelmiä | |
| JPWO2020168291A5 (https=) | ||
| JPWO2021202568A5 (https=) | ||
| CN117965505A (zh) | 工程化的腺苷脱氨酶及碱基编辑器 | |
| JP7001272B2 (ja) | ゲノム配列改変技術における変異導入効率の向上方法、及びそれに用いる分子複合体 | |
| JPWO2022056324A5 (https=) | ||
| JPWO2023039378A5 (https=) | ||
| CN118147120A (zh) | 胞苷脱氨酶及碱基编辑器 | |
| CN105602972B (zh) | 基于CRISPR-Cas9体外改造腺病毒载体的方法 | |
| WO2024125221A1 (zh) | 一种碱基编辑系统及碱基编辑方法 | |
| JPWO2023097282A5 (https=) | ||
| CN116529368A (zh) | 来自乳糖奈瑟氏菌的i-c型crispr系统和使用方法 | |
| WO2025094924A1 (ja) | 酵素、酵素複合体、および、これらの利用 | |
| KR20260013354A (ko) | CRISPR-Cas12b 시스템을 기반으로 한 단일 염기치환기술 | |
| Yasukawa et al. | Rolling-circle plasmid pKYM re-initiates DNA replication | |
| WO2023029492A1 (zh) | 一种外源基因定点整合的系统及方法 | |
| WO2023024089A1 (zh) | 实现a到c和/或a到t碱基突变的碱基编辑系统及其应用 | |
| HK40081180A (en) | Base editing enzymes | |
| WO2025104560A1 (en) | Identification of genomic sequences for ataxias and epilepsies treatment | |
| HK40035921A (en) | Method for modifying genome sequence to introduce specific mutation to targeted dna sequence by base-removal reaction, and molecular complex used therein |